| Literature DB >> 32443614 |
Ahmed M Naglah1,2, Mohamed A Al-Omar1, Abdulrahman A Almehizia1,3, Ahmad J Obaidullah3, Mashooq A Bhat3, Atef Kalmouch2, Asma S Al-Wasidi4, Jehan Y Al-Humaidi4, Moamen S Refat5,6.
Abstract
A new six intraperitoneal injections insulin-mimetic vanadyl(IV) compounds [(VO)(FA)(AAn)] (where n = 1-6: AA1 = isoleucine, AA2 = threonine, AA3 = proline, AA4 = phenylalanine, AA5 = lysine, and AA6 = glutamine) were synthesized by the chemical reactions between folic acid (FA), VOSO4, and amino acids (AAn) with equal molar ratio 1:1:1 in neutralized media. These complexes were characterized by elemental analysis and estimation of vanadyl(IV) metal ions. The thermal stability behavior of these complexes was studied by TG-DTG-DTA analyses. The structures of these complexes were elucidated by spectroscopic methods like infrared, electron spin resonance (ESR), and solid reflectance spectroscopes. The powder X-ray diffraction (XRD) study suggested the crystalline nature of the complexes. Magnetic moments and electronic spectra revealed the square-pyramid geometrical structure of the complexes. The conductivity results refereed that all synthesized vanadyl(IV) complexes were of a non-electrolyte behavior. The infrared spectra assignments of these complexes revealed that the FAH2 and AAn chelates act as a bidentate ligation. The chelation towards vanadyl (IV) ions existed via deprotonation of one of the carboxylic groups of FAH2 drug ligand, and so amino acids act as bidentate ligands via N-amino and O-carboxylate groups. Both scanning and transmission electron microscope (SEM and TEM) techniques were used to investigate the surface morphology. The main task of this research is the aim of designing a new insulin alternative antidiabetic drug agent. The antidiabetic efficiency of these complexes was evaluated in streptozotocin-induced diabetic male albino rats. Liver and kidney functions, insulin and blood glucose levels, lipid profile, and superoxide dismutase antioxidant (SOD) are verified identifiers for the efficiency of VO(IV)/FA/AAn system compounds as antidiabetic drug agents.Entities:
Keywords: VO2+ ion; amino acid; diabetes; drug; folic acid; insulin alternative; spectroscopic
Mesh:
Substances:
Year: 2020 PMID: 32443614 PMCID: PMC7277503 DOI: 10.3390/biom10050781
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Elemental analysis and physical data of NH4[(VO)(FA)(AAn)] complexes.
| Complex | M. wt. | % C | % H | % N | % V |
| Λm (Ω−1cm2 mol−1) |
|---|---|---|---|---|---|---|---|
| (calcd.)/found | |||||||
| NH4[(VO)(FA)(AA1)] | 654 | (45.87) | (5.04) | (19.26) | (7.79) | 2.1 | 19 |
| NH4[(VO)(FA)(AA2)] | 642 | (42.99) | (4.51) | (19.62) | (7.94) | 1.8 | 13 |
| NH4[(VO)(FA)(AA3)]·H2O | 656 | (43.90) | (4.72) | (19.20) | (7.77) | 1.7 | 24 |
| NH4[(VO)(FA)(AA4)]·6H2O | 796 | (42.21) | (5.40) | (15.82) | (6.40) | 2.1 | 17 |
| NH4[(VO)(FA)(AA5)] (C25H34N10O9V), V | 669 | (44.84) | (5.08) | (20.92) | (7.62) | 2.2 | 21 |
| NH4[(VO)(FA)(AA6)]·H2O | 687 | (41.92) | (4.65) | (20.37) | (7.42) | 2.2 | 23 |
Figure 1Electron spin resonance (ESR) spectra of NH4[(VO)(FA)(AAn)] complexes (where AA1 = isoleucine, AA2 = threonine, AA3 = proline, AA4 = phenylalanine, AA5 = lysine, and AA6 = glutamine) in solid-state.
Figure 2Infrared spectrum of NH4[(VO)(FA)(AA1)] complex (where AA1 = isoleucine).
IR frequencies (cm−1) of NH4[(VO)(FA)(AAn)] complexes.
| Compound | ν(O-H) | ν(N-H) | ν(C=O) | ν(COO−) | δ(NH3) | δ(NH2) | ν(V=O) | ν(M-O) | ν(M-N) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Asym | Sym | |||||||||
| FAH2 | 3539 | -- | 1694 | -- | -- | -- | 1607 | -- | -- | -- |
| AA1 | -- | 3060 | -- | 1582 | 1463 | 1513 | -- | -- | -- | -- |
| AA2 | -- | 3170 | -- | 1631 | 1420 | 1474 | -- | -- | -- | -- |
| AA3 | -- | 3064 | -- | 1624 | 1413 | 1490 | -- | -- | -- | -- |
| AA4 | -- | 3150 | -- | 1626 | 1415 | 1502 | -- | -- | -- | -- |
| AA5 | -- | 3049 | -- | 1582 | 1412 | 1517 | -- | -- | -- | -- |
| AA6 | -- | 3178 | -- | 1633 | 1416 | 1484 | -- | -- | -- | -- |
| I | 3384 | -- | 1688 | 1512 | 1409 | -- | 1609 | 1108 | 617 | 445 |
| II | 3387 | -- | 1686 | 1483 | 1409 | -- | 1613 | 1114 | 617 | 450 |
| III | 3390 | -- | 1687 | 1509 | 1408 | -- | 1610 | 1108 | 616 | 440 |
| IV | 3398 | -- | 1688 | 1505 | 1408 | -- | 1613 | 1112 | 616 | 460 |
| V | 3389 | -- | 1687 | 1509 | 1407 | -- | 1610 | 1112 | 617 | 455 |
| VI | 3400 | -- | 1687 | 1506 | 1410 | -- | 1610 | 1106 | 617 | 452 |
Figure 3Suggested structures of vanadyl(IV) complexes (R = complementary of amino acids).
Figure 4Thermogravimetric/differential thermogravimetric/differential thermal analysis (TG/DTG/DTA) curves of NH4[(VO)(FA)(AA1)] complex.
Figure 5X-ray diffraction (XRD) of the solid NH4[(VO)(FA)(AA1)] complex.
XRD diffraction patterns of the solid NH4[(VO)(FA)(AA1)] complex.
| FAH2 | AA1 | Vanadium Metal |
|---|---|---|
| 14.996, 16.870, 18.185, 20.620, 21.548, 22.862, 25.664, 28.293, and 36.738° | 12.735, 19.113, 32.235, and 35.79° | 38.612° |
Figure 6Transmission electron microscope (TEM) micrographs of the solid NH4[(VO)(FA)(AA1)] complex.
Effect of vanadyl(IV) complexes (I–VI) on insulin hormone, blood glucose level, serum GPT enzyme, creatinine, uric acid level, lactate dehydrogenase, glucose-6-phosphate dehydrogenase activities, hemoglobin levels, superoxide dismutase enzyme (SOD), and lipid profile in normal and diabetic rats.
| Biological Test | Group I | Group II | Group III | Group IV1 | Group IV2 | Group IV3 | Group IV4 | Group IV5 | Group IV6 |
|---|---|---|---|---|---|---|---|---|---|
| Insulin (IU/mL) | 58 ± 2 | 24 ± 3 | 41 ± 1 | 53 ± 1 | 48 ± 2 | 48 ± 2 | 49 ± 2 | 47 ± 1 | 48 ± 2 |
| Glucose (mg/dL) | 78 ± 5 | 410 ± 15 | 284 ± 9 | 191 ± 4 | 247 ± 6 | 249 ± 5 | 245 ± 5 | 225 ± 4 | 240 ± 5 |
| GPT (U/L) | 72 ± 7 | 112 ± 7 | 124 ± 11 | 90 ± 5 | 93 ± 6 | 91 ± 6 | 91 ± 4 | 90 ± 5 | 85 ± 4 |
| Creatinine (mg/dL) | 0.5 ± 0.1 | 1 ± 0.2 | 0.9 ± 0.2 | 0.6 ± 0.1 | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.1 | 0.7 ± 0.2 |
| Uric Acid (mg/dL) | 4 ± 0.2 | 5 ± 0.4 | 4 ± 0.3 | 4 ± 0.3 | 4 ± 0.3 | 4 ± 0.3 | 4 ± 0.2 | 4 ± 0.2 | 4 ± 0.2 |
| LDH (U/L) | 295 ± 15 | 410 ± 13 | 435 ± 20 | 355 ± 18 | 340 ± 22 | 359 ± 20 | 356 ± 26 | 330 ± 25 | 367 ± 19 |
| G6PD (U/L) | 12 ± 0.6 | 8 ± 0.5 | 9 ± 0.4 | 11 ± 0.6 | 11 ± 0.3 | 11 ± 0.4 | 11 ± 0.4 | 11 ± 0.4 | 11 ± 0.5 |
| hemoglobin (gldL) | 13 ± 0.4 | 10 ± 0.4 | 11 ± 0.5 | 14 ± 0.7 | 14 ± 0.5 | 14 ± 0.4 | 13 ± 0.6 | 14 ± 0.6 | 14 ± 0.5 |
| SOD (U/mL) | 308 ± 15 | 259 ± 22 | 280 ± 19 | 297 ± 25 | 290 ± 16 | 300 ± 20 | 297 ± 18 | 295 ± 22 | 302 ± 19 |
| Cholesterol (mg/dL) | 76 ± 8 | 211 ± 10.6 | 130 ± 9 | 102 ± 8 | 106 ± 5 | 101 ± 5 | 105 ± 7 | 104 ± 4 | 108 ± 5 |
| Triglyceride (mg/dL) | 140 ± 9 | 197 ± 12 | 157 ± 11 | 145 ± 8 | 149 ± 8 | 143 ± 9 | 145 ± 8 | 143 ± 7 | 143 ± 8 |
| HDL-c (mg/dL) | 42 ± 3 | 21 ± 2 | 32 ± 2 | 35 ± 3 | 35 ± 2 | 36 ± 3 | 37 ± 2 | 36 ± 3 | 36 ± 3 |
| LDL-c (mg/dL) | 31 ± 4 | 53 ± 5 | 43 ± 5 | 38 ± 4 | 42 ± 5 | 39 ± 4 | 39 ± 5 | 39 ± 4 | 38 ± 4 |
Figure 7(A) Normal control of the pancreas. Photomicrograph of normal pancreatic tissue showing normal-sized islet of Langerhans (↕) surrounded by normal pancreatic acini. Hematoxylin and eosin (H&E) stain ×400). (B) Positive diabetes mellitus (DM) control of the pancreas. Photomicrograph of pancreatic tissue of diabetic rat showing atrophy of the islet of Langerhans (↕) surrounded by normal pancreatic acini. (H&E stain ×400). (C) Positive DM control of the pancreas. Photomicrograph of pancreatic tissue of diabetic rat showing dilated congested vascular spaces (↕) surrounded by aggregates of inflammatory cells (↑) and pancreatic acini. (H&E stain ×400). (D) Pancreas of the treated group with VOSO4. Photomicrograph of pancreatic tissue of diabetic rat treated with VOSO4 showing slight increase in the islet of Langerhans (↕). (H&E stain ×400). (E) Pancreas of the treated group with VOSO4. Photomicrograph of pancreatic tissue of diabetic rat treated with VOSO4 showing still dilated congested vascular space (↕) surrounded by few aggregates of inflammatory cells (↑). (H&E stain ×400). (F) Pancreas of the treated group with [(FA)(VO)(AA1)(NH4)] complex. Photomicrograph of pancreatic tissue of diabetic rat treated with NH4[(VO)(FA)(AA1)] complex, showing a good response with return of islet of Langerhans (↕) to its normal size. (H&E stain ×400).
Figure 8(A) Normal liver control. Photomicrograph of normal liver tissue showing normal size central vein (↕) surrounded by rows and cords of normal hepatocytes (↑) with central nuclei and abundant eosinophilic cytom. (H&E stain ×400). (B) Positive control DM Liver. Photomicrograph of liver tissue of diabetic rat showing markedly dilated congested central vein (↕) filled with red blood cells and surrounded by aggregates of inflammatory cells with rows and cords of hepatocytes showing severe fatty change (↑). (H&E stain ×400). (C) Liver of treated group with VOSO4. Photomicrograph of liver tissue from a diabetic rat treated with only VOSO4, showing moderately dilated congested central vein (↕) surrounded by rows and cords of hepatocytes showing moderate degree of fatty change (↑). (H&E stain ×400). (D) Liver of treated group with NH4[(VO)(FA)(AA1)] complex. Photomicrograph of liver tissue of diabetic rat treated with NH4[(VO)(FA)(AA1)] complex showing return to the normal state with a normal size of central vein (↕) surrounded by rows and cords of normal hepatocytes (↑). (H&E stain ×400).